Published in Ther Clin Risk Manag on January 05, 2015
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm (2015) 0.89
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol (2016) 0.81
Dynamics of Th17 associating cytokines in Cryptosporidium parvum-infected mice. Parasitol Res (2015) 0.78
Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data. PLoS One (2016) 0.78
Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y) (2015) 0.77
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet (1992) 6.66
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology (2005) 5.92
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2007) 5.02
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut (2010) 4.50
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.83
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther (2014) 3.74
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther (2013) 3.47
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.35
Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 3.25
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01
Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 2.98
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology (2013) 2.97
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology (1992) 2.86
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 2.80
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med (2013) 2.53
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine (1995) 2.34
Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol (2008) 2.25
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med (2014) 2.04
Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther (2011) 2.02
Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology (2012) 1.97
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 1.95
Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol (2009) 1.86
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther (2014) 1.56
The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med (2014) 1.54
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther (2012) 1.53
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology (2003) 1.52
The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol (2012) 1.42
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol (2007) 1.39
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs (2010) 1.39
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis (2009) 1.25
Comparing functional results one year and ten years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Dis Colon Rectum (1994) 1.16
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther (2010) 1.14
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology (2013) 1.12
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol (2007) 1.08
Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis (2001) 1.00
Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther (2013) 1.00
Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol (2013) 0.99
An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol (2014) 0.98
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther (2010) 0.97
Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis (2013) 0.93
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis (2014) 0.83
Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol (2014) 0.82
Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks. Inflamm Bowel Dis (2014) 0.81
Need for infliximab dose intensification in Crohn's disease and ulcerative colitis. World J Gastroenterol (2014) 0.78
Still in pursuit. Gastroenterology (2013) 0.76
Infliximab for moderate to severe ulcerative colitis: the jury isn't in yet. Gastroenterology (2014) 0.76